NASDAQ:EPIX ESSA Pharma (EPIX) Stock Price, News & Analysis $5.34 -0.08 (-1.48%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$5.16▼$5.4950-Day Range$4.63▼$6.7552-Week Range$2.58▼$11.67Volume28,885 shsAverage Volume98,154 shsMarket Capitalization$236.88 millionP/E RatioN/ADividend YieldN/APrice Target$16.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ESSA Pharma alerts: Email Address ESSA Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside209.0% Upside$16.50 Price TargetShort InterestBearish2.28% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$4,823 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.83) to ($1.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.04 out of 5 starsMedical Sector633rd out of 936 stocksPharmaceutical Preparations Industry291st out of 436 stocks 3.5 Analyst's Opinion Consensus RatingESSA Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageESSA Pharma has only been the subject of 1 research reports in the past 90 days.Read more about ESSA Pharma's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted2.28% of the outstanding shares of ESSA Pharma have been sold short.Short Interest Ratio / Days to CoverESSA Pharma has a short interest ratio ("days to cover") of 18.7, which indicates bearish sentiment.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldESSA Pharma does not currently pay a dividend.Dividend GrowthESSA Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EPIX. Previous Next 2.9 News and Social Media Coverage News SentimentESSA Pharma has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ESSA Pharma this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for EPIX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ESSA Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,823.00 in company stock.Percentage Held by Insiders14.70% of the stock of ESSA Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.12% of the stock of ESSA Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ESSA Pharma's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ESSA Pharma are expected to decrease in the coming year, from ($0.83) to ($1.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ESSA Pharma is -8.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ESSA Pharma is -8.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioESSA Pharma has a P/B Ratio of 1.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ESSA Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThis TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.But I can promise that you’ll see all the details for yourself here. About ESSA Pharma Stock (NASDAQ:EPIX)ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Read More EPIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EPIX Stock News HeadlinesJuly 8, 2024 | prnewswire.comESSA Pharma to Present at the JonesHealthcare Seaside SummitMay 30, 2024 | prnewswire.comESSA Pharma to Present at the Jefferies Global Healthcare ConferenceJuly 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.May 21, 2024 | finance.yahoo.comInsider Stock Buying Reaches US$709.0k On ESSA PharmaMay 14, 2024 | markets.businessinsider.comBuy Rating Endorsed for ESSA Pharma on Robust Pipeline and Market Expansion PotentialMay 14, 2024 | prnewswire.comESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024April 9, 2024 | finance.yahoo.comESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 9, 2024 | prnewswire.comESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceJuly 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.April 8, 2024 | finance.yahoo.comESSA Pharma (NASDAQ:EPIX) Is In A Strong Position To Grow Its BusinessApril 7, 2024 | investing.comEssa Pharma COO sells shares worth over $5,500April 5, 2024 | morningstar.comESSA Pharma Inc EPIXMarch 10, 2024 | finance.yahoo.comEPIX Jul 2024 7.500 callMarch 10, 2024 | finance.yahoo.comEPIX Jul 2024 12.500 putMarch 7, 2024 | prnewswire.comESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERSFebruary 13, 2024 | benzinga.comESSA Pharma: Q1 Earnings InsightsFebruary 13, 2024 | finance.yahoo.comESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023February 8, 2024 | finance.yahoo.comESSA Pharma Inc Executive Peter Virsik Sells 72,782 SharesSee More Headlines Receive EPIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EPIX CUSIPN/A CIK1633932 Webwww.essapharma.com Phone778-331-0962Fax604-738-4080Employees50Year FoundedN/APrice Target and Rating Average Stock Price Target$16.50 High Stock Price Target$17.00 Low Stock Price Target$16.00 Potential Upside/Downside+209.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-19.46% Return on Assets-18.96% Debt Debt-to-Equity RatioN/A Current Ratio32.89 Quick Ratio32.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.30 per share Price / Book1.62Miscellaneous Outstanding Shares44,360,000Free Float37,842,000Market Cap$236.44 million OptionableOptionable Beta1.82 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. David Ross Parkinson M.D. (Age 74)President, CEO & Director Comp: $814.15kMr. David S. Wood C.M.A. (Age 67)CPA, CMA, CPA, M.B.A., MBA, Chief Financial Officer Comp: $590.39kMr. Peter A. Virsik M.B.A. (Age 53)M.S., Executive VP & COO Comp: $645.95kDr. Alessandra Cesano M.D. (Age 63)Ph.D., Chief Medical Officer & Executive VP Comp: $623.93kChandtip ChandhasinExecutiveErica OsbourneExecutiveErin RudsinskiExecutiveLoleta HarrisExecutiveNeil ThaparExecutiveNkengyal BarberExecutiveMore ExecutivesKey CompetitorsCronos GroupNASDAQ:CRONMesoblastNASDAQ:MESOPhibro Animal HealthNASDAQ:PAHC4D Molecular TherapeuticsNASDAQ:FDMTArbutus BiopharmaNASDAQ:ABUSView All CompetitorsInsiders & InstitutionsJanus Henderson Group PLCBought 85,760 shares on 5/16/2024Ownership: 2.657%Bellevue Group AGSold 9,000 shares on 5/15/2024Ownership: 17.834%EntryPoint Capital LLCBought 4,420 shares on 5/14/2024Ownership: 0.010%Peter VirsikSold 694 sharesTotal: $4,823.30 ($6.95/share)BNP Paribas Financial MarketsSold 14,971 shares on 5/1/2024Ownership: 0.096%View All Insider TransactionsView All Institutional Transactions EPIX Stock Analysis - Frequently Asked Questions How have EPIX shares performed this year? ESSA Pharma's stock was trading at $6.60 at the beginning of 2024. Since then, EPIX stock has decreased by 19.1% and is now trading at $5.34. View the best growth stocks for 2024 here. How were ESSA Pharma's earnings last quarter? ESSA Pharma Inc. (NASDAQ:EPIX) issued its earnings results on Tuesday, May, 14th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.01. How do I buy shares of ESSA Pharma? Shares of EPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ESSA Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ESSA Pharma investors own include RedHill Biopharma (RDHL), Aurinia Pharmaceuticals (AUPH), Lipocine (LPCN), Trevena (TRVN), Allena Pharmaceuticals (ALNA), Agile Therapeutics (AGRX). This page (NASDAQ:EPIX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ESSA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ESSA Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.